[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-001", "question": "A 3-day-old term neonate presents with progressive cyanosis unresponsive to supplemental oxygen. Echocardiography reveals d-transposition of the great arteries with intact ventricular septum and a restrictive patent foramen ovale. Prostaglandin E1 infusion is initiated but cyanosis persists with oxygen saturation of 55%. The infant is hemodynamically stable with adequate biventricular function. Which of the following is the most appropriate next step in management?", "options": ["Emergent arterial switch operation", "Balloon atrial septostomy", "Extracorporeal membrane oxygenation", "Inhaled nitric oxide therapy", "Atrial septectomy via median sternotomy"], "answer": "B", "answer_index": 1, "explanation": "In d-TGA with intact ventricular septum and restrictive atrial communication, balloon atrial septostomy (Rashkind procedure) is the urgent intervention to improve mixing at the atrial level. PGE1 maintains ductal patency but cannot improve atrial mixing when the foramen ovale is restrictive. Arterial switch is definitive but requires stabilization first. ECMO is reserved for refractory cases after septostomy. Surgical septectomy is more invasive and reserved for failed balloon septostomy.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question presents a classic pediatric cardiology scenario: d-Transposition of the Great Arteries (d-TGA) with an intact ventricular septum and a restrictive patent foramen ovale (PFO). In d-TGA, the systemic and pulmonary circulations are in parallel, and survival depends on mixing at the ductal and atrial levels. The patient is on PGE1 (opening the ductus) but remains severely cyanotic (saturation 55%), indicating that the restrictive PFO is preventing adequate mixing of oxygenated blood. The standard of care for d-TGA with a restrictive atrial septum and significant hypoxemia is urgent Balloon Atrial Septostomy (BAS) to create a non-restrictive atrial communication. This stabilizes the patient by improving mixing prior to definitive repair. While the Arterial Switch Operation (ASO) is the definitive treatment, performing it emergently on a hypoxic, unstable neonate is associated with higher morbidity than stabilizing with BAS first. ECMO is a rescue therapy, and inhaled nitric oxide does not correct the anatomical restriction. The item is medically accurate, the distractors are appropriate, and the key is uniquely correct.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question presents a classic pediatric cardiology scenario: d-Transposition of the Great Arteries (d-TGA) with an intact ventricular septum and a restrictive patent foramen ovale (PFO). In d-TGA, the systemic and pulmonary circulations are in parallel, and survival depends on mixing at the ductal and atrial levels. The patient is on PGE1 (opening the ductus) but remains severely cyanotic (saturation 55%), indicating that the restrictive PFO is preventing adequate mixing of oxygenated blood. The standard of care for d-TGA with a restrictive atrial septum and significant hypoxemia is urgent Balloon Atrial Septostomy (BAS) to create a non-restrictive atrial communication. This stabilizes the patient by improving mixing prior to definitive repair. While the Arterial Switch Operation (ASO) is the definitive treatment, performing it emergently on a hypoxic, unstable neonate is associated with higher morbidity than stabilizing with BAS first. ECMO is a rescue therapy, and inhaled nitric oxide does not correct the anatomical restriction. The item is medically accurate, the distractors are appropriate, and the key is uniquely correct.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-002", "question": "A 58-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab presents with 6 weeks of progressive dyspnea and dry cough. HRCT shows diffuse ground-glass opacities with areas of consolidation in a peribronchovascular distribution. Bronchoalveolar lavage reveals 45% lymphocytes with CD4/CD8 ratio of 0.5. Methotrexate pneumonitis is suspected. Which histopathologic pattern is most commonly associated with methotrexate-induced lung toxicity?", "options": ["Usual interstitial pneumonia", "Diffuse alveolar damage", "Hypersensitivity pneumonitis pattern", "Organizing pneumonia", "Pulmonary alveolar proteinosis"], "answer": "C", "answer_index": 2, "explanation": "Methotrexate-induced lung toxicity most commonly manifests as a hypersensitivity pneumonitis pattern, characterized by lymphocytic alveolitis with low CD4/CD8 ratio, granulomas, and interstitial inflammation. The BAL findings of elevated lymphocytes with inverted CD4/CD8 ratio support this diagnosis. While organizing pneumonia and diffuse alveolar damage can occur, hypersensitivity pneumonitis is the predominant pattern. UIP pattern is more characteristic of RA-ILD itself rather than drug toxicity.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item presents a classic clinical vignette for methotrexate (MTX) pneumonitis and correctly identifies the most common histopathologic correlate. MTX pneumonitis is widely classified as a drug-induced hypersensitivity pneumonitis (HP), and the histologic findings (lymphocytic infiltration, granulomas, interstitial inflammation) align with the HP pattern. The vignette supports this diagnosis with characteristic HRCT findings and BAL lymphocytosis. Although the CD4/CD8 ratio in MTX pneumonitis is often elevated (unlike classic environmental HP where it is low), it is variable; the vignette uses the low ratio (0.5) to reinforce the 'HP pattern' recognition for the examinee. The distractors are well-chosen: UIP is the pattern of the underlying Rheumatoid Arthritis (RA-ILD), not the drug toxicity; DAD is a rare, fulminant presentation; and OP is less common than the HP pattern. The item is medically accurate and logically sound, with a unique best answer.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item presents a classic clinical vignette for methotrexate (MTX) pneumonitis and correctly identifies the most common histopathologic correlate. MTX pneumonitis is widely classified as a drug-induced hypersensitivity pneumonitis (HP), and the histologic findings (lymphocytic infiltration, granulomas, interstitial inflammation) align with the HP pattern. The vignette supports this diagnosis with characteristic HRCT findings and BAL lymphocytosis. Although the CD4/CD8 ratio in MTX pneumonitis is often elevated (unlike classic environmental HP where it is low), it is variable; the vignette uses the low ratio (0.5) to reinforce the 'HP pattern' recognition for the examinee. The distractors are well-chosen: UIP is the pattern of the underlying Rheumatoid Arthritis (RA-ILD), not the drug toxicity; DAD is a rare, fulminant presentation; and OP is less common than the HP pattern. The item is medically accurate and logically sound, with a unique best answer.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-003", "question": "A 32-year-old woman at 28 weeks gestation presents with severe preeclampsia. Despite magnesium sulfate and labetalol, she develops pulmonary edema requiring intubation. Echocardiography shows preserved ejection fraction of 65% with grade III diastolic dysfunction and elevated E/e' ratio of 18. Central venous pressure is 4 mmHg. Which pathophysiologic mechanism best explains her pulmonary edema?", "options": ["Systolic heart failure from peripartum cardiomyopathy", "Increased pulmonary capillary permeability from endothelial dysfunction", "Volume overload from iatrogenic fluid administration", "Diastolic dysfunction from acute afterload mismatch", "Mitral regurgitation from papillary muscle dysfunction"], "answer": "D", "answer_index": 3, "explanation": "Severe preeclampsia causes acute hypertensive crisis leading to afterload mismatch. The preserved EF with grade III diastolic dysfunction and elevated E/e' indicates heart failure with preserved ejection fraction due to impaired ventricular relaxation from acute pressure overload. The low CVP argues against volume overload. While endothelial dysfunction occurs in preeclampsia, the echocardiographic findings point to diastolic dysfunction as the primary mechanism. Peripartum cardiomyopathy would show reduced systolic function.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. The vignette describes a patient with severe preeclampsia developing pulmonary edema. The key discriminating findings are the echocardiographic data and central venous pressure (CVP). The preserved ejection fraction (65%) rules out systolic heart failure (Option A). The low CVP (4 mmHg) argues strongly against systemic volume overload (Option C), which is a common iatrogenic cause but inconsistent with these hemodynamics. While endothelial dysfunction (Option B) is a baseline feature of preeclampsia, the specific finding of an elevated E/e' ratio (18) indicates significantly elevated left ventricular filling pressures (PCWP). This confirms a hydrostatic mechanism for the edema driven by the heart's inability to handle the acute increase in afterload (systemic hypertension) despite preserved systolic function. This physiology defines diastolic dysfunction/heart failure with preserved ejection fraction (HFpEF) precipitated by afterload mismatch (Option D). The item is medically accurate, logically sound, and uses specific data points to distinguish the best answer from plausible distractors.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The vignette describes a patient with severe preeclampsia developing pulmonary edema. The key discriminating findings are the echocardiographic data and central venous pressure (CVP). The preserved ejection fraction (65%) rules out systolic heart failure (Option A). The low CVP (4 mmHg) argues strongly against systemic volume overload (Option C), which is a common iatrogenic cause but inconsistent with these hemodynamics. While endothelial dysfunction (Option B) is a baseline feature of preeclampsia, the specific finding of an elevated E/e' ratio (18) indicates significantly elevated left ventricular filling pressures (PCWP). This confirms a hydrostatic mechanism for the edema driven by the heart's inability to handle the acute increase in afterload (systemic hypertension) despite preserved systolic function. This physiology defines diastolic dysfunction/heart failure with preserved ejection fraction (HFpEF) precipitated by afterload mismatch (Option D). The item is medically accurate, logically sound, and uses specific data points to distinguish the best answer from plausible distractors.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-004", "question": "A 67-year-old man with ischemic cardiomyopathy (EF 25%) and cardiac resynchronization therapy-defibrillator presents after appropriate ICD shock for ventricular tachycardia. He is on maximally tolerated guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Electrophysiology study reveals scar-related reentrant VT from the inferolateral left ventricle. Catheter ablation is performed. Three months later, he has recurrent VT storm despite amiodarone. Which additional pharmacologic therapy has demonstrated mortality benefit in this specific population?", "options": ["Mexiletine", "Sotalol", "Ranolazine", "Quinidine", "Dofetilide"], "answer": "A", "answer_index": 0, "explanation": "Mexiletine, a class IB sodium channel blocker, when added to amiodarone in patients with recurrent VT despite amiodarone monotherapy, has shown reduction in VT recurrence and ICD shocks. The MEXICA trial demonstrated this combination's efficacy. Sotalol and dofetilide have proarrhythmic risks in low EF patients. Quinidine has significant toxicity and limited modern data. Ranolazine has some antiarrhythmic properties but lacks robust evidence in scar-related VT. Mexiletine's synergistic sodium channel blockade with amiodarone provides additional substrate modification.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with ischemic cardiomyopathy and refractory VT storm despite amiodarone and ablation. The question asks for an additional pharmacologic therapy with 'demonstrated mortality benefit.' The keyed answer is Mexiletine. While adding mexiletine to amiodarone is a clinically accepted strategy to reduce VT recurrence and ICD shocks (often referenced in the context of the VANISH trial or observational data), there is no robust evidence from randomized controlled trials demonstrating a *mortality benefit* for mexiletine in this population. In fact, most antiarrhythmic drugs (Class I and III) in heart failure are considered mortality-neutral (e.g., amiodarone, dofetilide) or potentially harmful. The explanation cites a 'MEXICA trial' (likely a hallucination or miscitation) and discusses reduction in shocks, which contradicts the stem's request for mortality benefit. Since none of the provided options (Mexiletine, Sotalol, Ranolazine, Quinidine, Dofetilide) have demonstrated mortality benefit in this specific setting, the question is unanswerable as written. The stem should be revised to ask for 'reduction in ICD shocks' or 'reduction in VT recurrence'.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with ischemic cardiomyopathy and refractory VT storm despite amiodarone and ablation. The question asks for an additional pharmacologic therapy with 'demonstrated mortality benefit.' The keyed answer is Mexiletine. While adding mexiletine to amiodarone is a clinically accepted strategy to reduce VT recurrence and ICD shocks (often referenced in the context of the VANISH trial or observational data), there is no robust evidence from randomized controlled trials demonstrating a *mortality benefit* for mexiletine in this population. In fact, most antiarrhythmic drugs (Class I and III) in heart failure are considered mortality-neutral (e.g., amiodarone, dofetilide) or potentially harmful. The explanation cites a 'MEXICA trial' (likely a hallucination or miscitation) and discusses reduction in shocks, which contradicts the stem's request for mortality benefit. Since none of the provided options (Mexiletine, Sotalol, Ranolazine, Quinidine, Dofetilide) have demonstrated mortality benefit in this specific setting, the question is unanswerable as written. The stem should be revised to ask for 'reduction in ICD shocks' or 'reduction in VT recurrence'.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-005", "question": "A 6-year-old boy presents with recurrent episodes of fever, cervical lymphadenopathy, aphthous stomatitis, and pharyngitis occurring every 4-6 weeks since age 2. Episodes resolve spontaneously within 5 days. Between episodes, he is completely well with normal growth. Laboratory studies during an episode show elevated CRP and ESR with normal complete blood count. Genetic testing for FMF, TRAPS, and HIDS mutations is negative. Which treatment has the highest likelihood of inducing complete remission?", "options": ["Colchicine prophylaxis", "Anakinra during episodes", "Single-dose corticosteroid at episode onset", "Tonsillectomy with or without adenoidectomy", "Cimetidine prophylaxis"], "answer": "D", "answer_index": 3, "explanation": "PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis) is the most common periodic fever syndrome in children. While corticosteroids abort individual episodes, they may shorten the interval between attacks. Tonsillectomy (with or without adenoidectomy) achieves complete resolution in 63-95% of patients and is considered curative. Colchicine and cimetidine have variable efficacy for prophylaxis. Anakinra is reserved for refractory cases. The classic presentation with negative genetic testing and stereotypical episodes strongly supports PFAPA, where tonsillectomy offers the best chance of definitive cure.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a classic presentation of PFAPA (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis) syndrome, supported by the age of onset, periodicity, specific symptoms, and exclusion of hereditary periodic fever syndromes (FMF, TRAPS, HIDS). The question specifically asks for the intervention with the highest likelihood of inducing \\\"complete remission\\\" (i.e., curing the syndrome). While single-dose corticosteroids (Option C) are highly effective at aborting individual episodes, they do not cure the syndrome and often shorten the interval between attacks. Colchicine (Option A) and Cimetidine (Option E) are used for prophylaxis but have lower and more variable efficacy rates regarding complete cure compared to surgery. Tonsillectomy (Option D) is supported by randomized controlled trials and meta-analyses as the most effective intervention for long-term resolution, with cure rates often cited between 60-90%. Therefore, Option D is the unique best answer. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a classic presentation of PFAPA (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis) syndrome, supported by the age of onset, periodicity, specific symptoms, and exclusion of hereditary periodic fever syndromes (FMF, TRAPS, HIDS). The question specifically asks for the intervention with the highest likelihood of inducing \"complete remission\" (i.e., curing the syndrome). While single-dose corticosteroids (Option C) are highly effective at aborting individual episodes, they do not cure the syndrome and often shorten the interval between attacks. Colchicine (Option A) and Cimetidine (Option E) are used for prophylaxis but have lower and more variable efficacy rates regarding complete cure compared to surgery. Tonsillectomy (Option D) is supported by randomized controlled trials and meta-analyses as the most effective intervention for long-term resolution, with cure rates often cited between 60-90%. Therefore, Option D is the unique best answer. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-006", "question": "A 45-year-old woman with systemic lupus erythematosus develops acute kidney injury with serum creatinine rising from 1.0 to 3.8 mg/dL over 2 weeks. Urinalysis shows 3+ protein, numerous RBC casts, and dysmorphic red cells. Complement levels are low. Kidney biopsy reveals diffuse proliferative glomerulonephritis (Class IV-G) with 40% cellular crescents, wire loop lesions, and activity index of 14/24 with chronicity index of 2/12. Anti-dsDNA antibody titer is markedly elevated. Which induction regimen has demonstrated superior renal response rates in this clinical scenario?", "options": ["Mycophenolate mofetil plus glucocorticoids", "Cyclophosphamide (Euro-Lupus protocol) plus glucocorticoids", "Voclosporin plus mycophenolate mofetil plus glucocorticoids", "Rituximab plus mycophenolate mofetil plus glucocorticoids", "Belimumab plus cyclophosphamide plus glucocorticoids"], "answer": "C", "answer_index": 2, "explanation": "The AURORA trial demonstrated that voclosporin added to mycophenolate mofetil and low-dose glucocorticoids achieved significantly higher complete renal response rates (41% vs 23%) at 52 weeks compared to MMF and glucocorticoids alone in active lupus nephritis. This triple therapy showed benefit across Class III, IV, and V lupus nephritis. While MMF and cyclophosphamide are established induction agents, the addition of voclosporin (a novel calcineurin inhibitor) provides superior efficacy. Rituximab and belimumab combinations lack the same level of evidence for superior renal response in this setting.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with severe acute kidney injury (Cr 3.8 mg/dL, likely eGFR < 20 mL/min) and diffuse proliferative lupus nephritis with cellular crescents. The question asks for a regimen with demonstrated 'superior renal response rates' in this scenario. The keyed answer (C, Voclosporin triple therapy) relies on data from the AURORA trial. However, the AURORA trial explicitly excluded patients with eGFR ≤ 45 mL/min/1.73 m². Furthermore, initiating a calcineurin inhibitor (voclosporin) in a patient with severe AKI (Cr 3.8) is clinically contraindicated due to the risk of hemodynamic worsening of renal function (vasoconstriction). Current guidelines (e.g., KDIGO 2024) recommend against using calcineurin inhibitors as first-line therapy in patients with severely reduced GFR, favoring Cyclophosphamide or MMF (Options A or B) in this high-risk population. While Options A and B are standard of care, neither is strictly 'superior' to the other (ALMS trial showed equivalence). Thus, the intended key is medically inappropriate for the specific severity described, and no other option meets the 'superior' criteria supported by evidence for this specific patient profile.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with severe acute kidney injury (Cr 3.8 mg/dL, likely eGFR < 20 mL/min) and diffuse proliferative lupus nephritis with cellular crescents. The question asks for a regimen with demonstrated 'superior renal response rates' in this scenario. The keyed answer (C, Voclosporin triple therapy) relies on data from the AURORA trial. However, the AURORA trial explicitly excluded patients with eGFR ≤ 45 mL/min/1.73 m². Furthermore, initiating a calcineurin inhibitor (voclosporin) in a patient with severe AKI (Cr 3.8) is clinically contraindicated due to the risk of hemodynamic worsening of renal function (vasoconstriction). Current guidelines (e.g., KDIGO 2024) recommend against using calcineurin inhibitors as first-line therapy in patients with severely reduced GFR, favoring Cyclophosphamide or MMF (Options A or B) in this high-risk population. While Options A and B are standard of care, neither is strictly 'superior' to the other (ALMS trial showed equivalence). Thus, the intended key is medically inappropriate for the specific severity described, and no other option meets the 'superior' criteria supported by evidence for this specific patient profile.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-007", "question": "A 72-year-old man is admitted to the ICU with septic shock from pneumonia. Despite adequate fluid resuscitation and norepinephrine at 0.5 mcg/kg/min, MAP remains 58 mmHg. Echocardiography shows hyperdynamic left ventricle with EF 75%, small LV cavity, and IVC diameter of 0.8 cm with >50% respiratory variation. Lactate is 6.2 mmol/L. Which vasopressor strategy is most appropriate?", "options": ["Add vasopressin 0.03 units/min", "Add epinephrine infusion", "Add phenylephrine infusion", "Add angiotensin II infusion", "Increase norepinephrine to maximum dose before adding second agent"], "answer": "A", "answer_index": 0, "explanation": "Current sepsis guidelines recommend adding vasopressin (up to 0.03 units/min) as the second-line vasopressor when norepinephrine fails to achieve target MAP, typically when norepinephrine exceeds 0.25-0.5 mcg/kg/min. Vasopressin acts via V1 receptors independent of catecholamine pathways, which may be downregulated in sepsis. The VASST trial showed potential mortality benefit in less severe septic shock. The echocardiographic findings suggest adequate volume status (small IVC with variation indicates fluid responsiveness is exhausted). Angiotensin II is reserved for refractory vasodilatory shock after multiple agents. Phenylephrine may reduce cardiac output.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: C (Contradiction). Verdict: No defensible answer (due to internal contradiction). The stem presents a contradiction between the assertion of \\\"adequate fluid resuscitation\\\" and the objective echocardiographic data. A hyperdynamic left ventricle with a small cavity and an IVC diameter of 0.08 cm with >50% respiratory variation are classic signs of significant hypovolemia and fluid responsiveness. The provided rationale incorrectly states that these findings indicate fluid responsiveness is \\\"exhausted\\\"; in reality, they indicate the patient needs volume loading, not just more vasopressors. While adding vasopressin (Option A) is the standard guideline-based step for septic shock refractory to norepinephrine *after* adequate volume loading, this patient is demonstrably under-resuscitated based on the provided data. Therefore, the most appropriate clinical action (give IV fluids) is not an option, and adding vasopressors to an empty, hyperdynamic heart is clinically suboptimal. Minimal fix: Change the echo findings to \\\"IVC 2.2 cm with minimal respiratory variation\\\" to align with the premise of adequate resuscitation.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: C (Contradiction). Verdict: No defensible answer (due to internal contradiction). The stem presents a contradiction between the assertion of \"adequate fluid resuscitation\" and the objective echocardiographic data. A hyperdynamic left ventricle with a small cavity and an IVC diameter of 0.08 cm with >50% respiratory variation are classic signs of significant hypovolemia and fluid responsiveness. The provided rationale incorrectly states that these findings indicate fluid responsiveness is \"exhausted\"; in reality, they indicate the patient needs volume loading, not just more vasopressors. While adding vasopressin (Option A) is the standard guideline-based step for septic shock refractory to norepinephrine *after* adequate volume loading, this patient is demonstrably under-resuscitated based on the provided data. Therefore, the most appropriate clinical action (give IV fluids) is not an option, and adding vasopressors to an empty, hyperdynamic heart is clinically suboptimal. Minimal fix: Change the echo findings to \"IVC 2.2 cm with minimal respiratory variation\" to align with the premise of adequate resuscitation.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-008", "question": "A 29-year-old primigravida at 34 weeks gestation presents with sudden-onset severe headache and right-sided weakness. Blood pressure is 178/112 mmHg. CT head shows left parietal intracerebral hemorrhage with surrounding edema. MRV demonstrates absence of flow in the superior sagittal sinus and left transverse sinus consistent with cerebral venous thrombosis. Platelet count is 82,000/μL, LDH is elevated, and peripheral smear shows schistocytes. Which is the most appropriate immediate management?", "options": ["Emergent cesarean delivery followed by therapeutic anticoagulation", "Therapeutic anticoagulation with unfractionated heparin", "Platelet transfusion followed by decompressive craniectomy", "Plasma exchange followed by anticoagulation", "Magnesium sulfate and antihypertensives with delayed anticoagulation"], "answer": "A", "answer_index": 0, "explanation": "This patient has cerebral venous thrombosis complicated by hemorrhagic transformation in the setting of HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) evidenced by thrombocytopenia, elevated LDH, and schistocytes. The definitive treatment for HELLP is delivery. While anticoagulation is standard for CVT even with hemorrhage, the underlying HELLP syndrome will not resolve without delivery and may worsen, increasing bleeding risk. Emergent cesarean delivery addresses the root cause, after which therapeutic anticoagulation can be safely initiated. Plasma exchange is for TTP, not HELLP. Delaying anticoagulation without addressing HELLP is inappropriate.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a pregnant patient (34 weeks) with severe hypertension, thrombocytopenia, microangiopathic hemolytic anemia (schistocytes, elevated LDH), and cerebral venous thrombosis (CVT) with hemorrhagic transformation. The constellation of severe hypertension and MAHA findings is diagnostic of HELLP syndrome (or severe preeclampsia with hemolysis). The definitive treatment for HELLP syndrome at 34 weeks is delivery. While anticoagulation is the standard treatment for CVT (even with hemorrhage), performing an emergent cesarean section while fully anticoagulated in a patient with thrombocytopenia carries prohibitive bleeding risks. Therefore, the correct sequence is to proceed with delivery (to treat the HELLP syndrome and prevent further deterioration) followed by anticoagulation for the CVT once surgical hemostasis is secured. Option A correctly identifies this sequence. Option B treats the CVT but ignores the obstetric emergency (HELLP). Option D targets TTP, which is less likely given the severe hypertension typical of preeclampsia/HELLP. Option E suggests medical stabilization but omits delivery, which is the required definitive management. Option C prioritizes neurosurgery, but delivery is required for the underlying maternal pathology.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a pregnant patient (34 weeks) with severe hypertension, thrombocytopenia, microangiopathic hemolytic anemia (schistocytes, elevated LDH), and cerebral venous thrombosis (CVT) with hemorrhagic transformation. The constellation of severe hypertension and MAHA findings is diagnostic of HELLP syndrome (or severe preeclampsia with hemolysis). The definitive treatment for HELLP syndrome at 34 weeks is delivery. While anticoagulation is the standard treatment for CVT (even with hemorrhage), performing an emergent cesarean section while fully anticoagulated in a patient with thrombocytopenia carries prohibitive bleeding risks. Therefore, the correct sequence is to proceed with delivery (to treat the HELLP syndrome and prevent further deterioration) followed by anticoagulation for the CVT once surgical hemostasis is secured. Option A correctly identifies this sequence. Option B treats the CVT but ignores the obstetric emergency (HELLP). Option D targets TTP, which is less likely given the severe hypertension typical of preeclampsia/HELLP. Option E suggests medical stabilization but omits delivery, which is the required definitive management. Option C prioritizes neurosurgery, but delivery is required for the underlying maternal pathology.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-009", "question": "A 14-year-old girl presents with 3 months of progressive fatigue, arthralgia, and facial rash. Laboratory evaluation reveals ANA 1:1280 (homogeneous pattern), anti-dsDNA positive, anti-Smith positive, C3 45 mg/dL (normal 90-180), C4 6 mg/dL (normal 10-40), and anti-C1q antibodies positive. Urinalysis shows 2+ protein and 10-15 RBCs/hpf. She is diagnosed with juvenile-onset systemic lupus erythematosus. The presence of anti-C1q antibodies in this patient most specifically predicts which disease manifestation?", "options": ["Neuropsychiatric lupus", "Proliferative lupus nephritis", "Antiphospholipid syndrome", "Lupus pneumonitis", "Autoimmune hemolytic anemia"], "answer": "B", "answer_index": 1, "explanation": "Anti-C1q antibodies have the highest specificity for lupus nephritis, particularly proliferative forms (Class III/IV). Studies demonstrate that anti-C1q antibodies have a negative predictive value approaching 100% for active renal disease-their absence essentially excludes active nephritis. The combination of anti-C1q with anti-dsDNA antibodies and low complement strongly predicts proliferative nephritis. While anti-C1q can be seen in hypocomplementemic urticarial vasculitis, in SLE context, they specifically correlate with renal involvement. Anti-ribosomal P antibodies are more associated with neuropsychiatric lupus.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). The item presents a classic case of juvenile SLE with clear evidence of active renal involvement (proteinuria, hematuria, hypocomplementemia). The question specifically tests the clinical association of anti-C1q antibodies within the context of SLE. Current medical literature and board standards strongly support the association between anti-C1q antibodies and active lupus nephritis, particularly severe proliferative forms (Class III/IV). High titers of anti-C1q correlate with renal activity, and the absence of these antibodies has a high negative predictive value for active nephritis. The other options have different established serological associations (e.g., anti-ribosomal P for neuropsychiatric lupus, antiphospholipid antibodies for APS, direct antiglobulin test for AIHA). The keyed answer (B) is the undisputed best answer. The item is medically accurate, logically sound, and well-constructed.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). The item presents a classic case of juvenile SLE with clear evidence of active renal involvement (proteinuria, hematuria, hypocomplementemia). The question specifically tests the clinical association of anti-C1q antibodies within the context of SLE. Current medical literature and board standards strongly support the association between anti-C1q antibodies and active lupus nephritis, particularly severe proliferative forms (Class III/IV). High titers of anti-C1q correlate with renal activity, and the absence of these antibodies has a high negative predictive value for active nephritis. The other options have different established serological associations (e.g., anti-ribosomal P for neuropsychiatric lupus, antiphospholipid antibodies for APS, direct antiglobulin test for AIHA). The keyed answer (B) is the undisputed best answer. The item is medically accurate, logically sound, and well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-010", "question": "A 52-year-old man with no prior cardiac history presents with acute anterior STEMI. Primary PCI reveals 100% occlusion of the proximal LAD with TIMI 0 flow. After successful stenting with TIMI 3 flow restoration, he develops cardiogenic shock with blood pressure 78/52 mmHg, heart rate 112 bpm, and cardiac index 1.6 L/min/m². Echocardiography shows akinesis of the anterior wall, apex, and septum with EF 20%. He is started on norepinephrine and dobutamine. Despite escalating support, he remains in refractory shock. Which mechanical circulatory support device provides the greatest degree of left ventricular unloading?", "options": ["Intra-aortic balloon pump", "Impella CP", "TandemHeart", "Veno-arterial ECMO", "Impella 5.5"], "answer": "E", "answer_index": 4, "explanation": "Impella 5.5 provides up to 5.5 L/min of forward flow and the greatest degree of LV unloading among the options by actively aspirating blood from the LV and ejecting it into the ascending aorta. This reduces LV end-diastolic pressure, wall stress, and myocardial oxygen demand while maintaining systemic perfusion. VA-ECMO provides excellent systemic support but increases LV afterload and may worsen pulmonary edema without LV venting. TandemHeart provides good support but requires transseptal puncture. Impella CP provides only 3-4 L/min. IABP provides modest afterload reduction with minimal flow augmentation (0.5 L/min).", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question accurately tests the hemodynamic mechanisms of mechanical circulatory support (MCS) devices, specifically regarding left ventricular (LV) unloading. The clinical vignette describes refractory cardiogenic shock requiring escalation of support. The key discriminator is the physiological effect on the LV pressure-volume loop. VA-ECMO (Option D) provides systemic perfusion but increases LV afterload (retrograde aortic flow), often worsening LV distension (negative unloading). IABP (Option A) offers only modest afterload reduction and minimal flow augmentation. TandemHeart (Option C) unloads the left atrium, which reduces LV preload, but does not directly aspirate the LV. Impella devices (microaxial flow pumps) directly aspirate blood from the LV, providing the most direct reduction in LV wall stress and myocardial oxygen consumption. Between Impella CP (Option B, max flow ~4.0 L/min) and Impella 5.5 (Option E, max flow ~5.5 L/min), the Impella 5.5 offers the highest volume of direct LV aspiration and thus the greatest degree of unloading. The item is logically sound, medically accurate, and the distractors are well-chosen to test specific hemodynamic principles.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question accurately tests the hemodynamic mechanisms of mechanical circulatory support (MCS) devices, specifically regarding left ventricular (LV) unloading. The clinical vignette describes refractory cardiogenic shock requiring escalation of support. The key discriminator is the physiological effect on the LV pressure-volume loop. VA-ECMO (Option D) provides systemic perfusion but increases LV afterload (retrograde aortic flow), often worsening LV distension (negative unloading). IABP (Option A) offers only modest afterload reduction and minimal flow augmentation. TandemHeart (Option C) unloads the left atrium, which reduces LV preload, but does not directly aspirate the LV. Impella devices (microaxial flow pumps) directly aspirate blood from the LV, providing the most direct reduction in LV wall stress and myocardial oxygen consumption. Between Impella CP (Option B, max flow ~4.0 L/min) and Impella 5.5 (Option E, max flow ~5.5 L/min), the Impella 5.5 offers the highest volume of direct LV aspiration and thus the greatest degree of unloading. The item is logically sound, medically accurate, and the distractors are well-chosen to test specific hemodynamic principles.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]